Retaining patients in buprenorphine treatment is essential in maximising treatment outcomes and minimising mortality risk. Delivery of treatment via novel depot buprenorphine products has the potential to enhance patient adherence and retention in treatment.
Treatment and Intervention
Heroin dependence is a chronic relapsing condition, associated with high levels of psychopathology. On entry to treatment approximately one quarter of heroin users meet criteria for Major Depression (MD), and this comorbidity has been linked to poorer treatment outcomes.
This PhD project will examine untreated remission from alcohol problems. This will involve understanding the way in which those with alcohol problems engage in ‘spontaneous remission’ or ‘natural recovery’ outside the treatment setting.
This project will used linked administrative data to understand risk for mortality and other adverse outcomes during and after opioid agonist treatment (OAT). It will use standard biostatistical approaches and sophisticated machine learning techniques.
This project attempts to understand the global epidemiology of infectious disease among prisoners in all countries.
Alcohol and other drug (AOD) treatment is key for improving health and reducing the social impact of AOD use. However, the treatment itself is not the only variable that impacts on whether health outcomes are improved.
The Australian National Advisory Council on Alcohol and Drugs (ANACAD) has funded NDARC to conduct a feasibility study for an early warning system (EWS) project, involving a data collection model that allows rapid triangulation of existing data to provide an early warning and current assessment o
This translational research project will embed screening, brief intervention and referral into community pharmacy practice, in addition to establishing clear referral pathways with primary, secondary and tertiary treatment service